Two infusions of natalizumab (300 mg or 3 mg/kg) showed no clear difference in adverse events up to week 12 compared with placebo (moderate certainty).
Two infusions of natalizumab (300 mg or 3 mg/kg) showed no clear difference in serious adverse events up to week 12 compared with placebo (low certainty).
Two infusions of natalizumab (300 mg or 3 mg/kg) showed no clear difference in withdrawal due to adverse events up to week 12 compared with placebo (low certainty).
Three infusions of natalizumab (300 mg) and two infusions of… showed no clear difference in adverse events up to week 10 compared with placebo and two infusions of infliximab (moderate certainty).
Three infusions of natalizumab (300 mg) and two infusions of… showed no clear difference in serious adverse events up to week 10 compared with placebo and two infusions of infliximab (low certainty).
Three infusions of natalizumab (300 mg) and two infusions of… showed no clear difference in withdrawal due to adverse events up to week 10 compared with placebo and two infusions of infliximab (low certainty).